AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

169.500

-1.710-1.00%

Volume:1.09M

Turnover:184.05M

Market Cap:81.18B

PE:-22.70

High:170.190

Open:169.660

Low:166.680

Close:171.210

52wk High:216.771

52wk Low:88.845

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.06

T/O Rate:0.23%

Dividend:4.07

Dividend Rate:2.40%

EPS(TTM):-7.465

EPS(LYR):-7.465

ROE:-15.83%

ROA:7.26%

PB:3.93

PE(LYR):-22.70

Loading ...

Overview Company News Filings

3 Dividend Powerhouses for More Reliable Income in Volatile Markets

Simply Wall St.

3 Australian Dividend Stocks Paying Over 5% That Income Investors May Want To Check

Simply Wall St.

Pediatric ANDEMBRY Phase 3b Success Might Change The Case For Investing In CSL (ASX:CSL)

Simply Wall St.

CSL Says European Commission Revokes Marketing Authorization for Tavneos

MT Newswires Live

Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End

EU Revokes Marketing Authorisation for CSL-Partnered Tavneos in EU, EEA

CSL Ltd - European Commission Adopts Decision to Revoke Marketing Authorisation for Tavneos in the European Union and European Economic Area Countries

THOMSON REUTERS

CSL Ltd - Tavneos Will no Longer be Available for Prescribing in the EU and Eea

THOMSON REUTERS

CSL Ltd - Committed to Implementing Decision in Full

THOMSON REUTERS

US FDA Approves First mRNA Flu Shot from Moderna

QBE Stock Leads 3 Australian Dividend Shares Offering Income and Quality

Simply Wall St.

CSL Sets Investor Briefing for Full-Year Results

iBio Names Endocrinologist Molly Carr as Chief Medical Officer

Australian Dividend Stocks Worth A Closer Look For Long Term Income

Simply Wall St.

CSL Stock And Australian Gold Miners Offering Dividend Yield Above 3%

Simply Wall St.

CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value

Simply Wall St.

CSL Stock And 2 Australian Dividend Shares Backed By Earnings

Simply Wall St.

Australian Shares Log Best Month Since February as Rate-hike Worries Ease

CSL Stock And QBE Shares For Dividend Income Above 3%

Simply Wall St.

Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/CSL.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":169.5,"timestamp":1789020720000,"preClose":171.21,"halted":0,"volume":1090729,"delay":0,"changeRate":-0.009987734361310717,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.4648732366853165,"marketStatus":"Not Yet Opened","change":-1.71,"latestTime":"09-10 16:12:00 AEST","open":169.66,"high":170.19,"low":166.68,"amount":184052300,"amplitude":0.020501,"askPrice":169.58,"askSize":200,"bidPrice":168.5,"bidSize":980,"shortable":3,"etf":0,"ttmEps":-7.4648732366853165,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":171.21,"dividendRate":0.02404,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.058942,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":171.21,"auctionPrice":169.5,"auctionVolume":397713,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020604080}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.465394,"volumeRatio":1.058942,"shares":478911979,"dividePrice":4.07457,"high":170.19,"amplitude":0.020501,"preClose":171.21,"low":166.68,"week52Low":88.845,"pbRate":"3.93","psRate":"3.68","week52High":216.771,"institutionHeld":0,"latestPrice":169.5,"committee":0.661017,"eps":-7.4653940611743685,"divideRate":0.024039,"volume":1090729,"delay":0,"ttmEps":-7.4653940611743685,"open":169.66,"prevYearClose":168.21,"prevWeekClose":172.243,"prevMonthClose":169.351,"prevQuarterClose":113.256,"fiveDayClose":173.23,"twentyDayClose":135.741,"sixtyDayClose":106.682,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658762016","title":"3 Dividend Powerhouses for More Reliable Income in Volatile Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2658762016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658762016?lang=en_us&edition=fundamental","pubTime":"2026-08-09 07:37","pubTimestamp":1786232240,"startTime":"0","endTime":"0","summary":"With global government bond yields swinging on every new inflation print, income investors are feeling the squeeze. Reliable bond income now looks less predictable, yet cash still loses ground when prices rise. That is where high quality dividend powerhouses can help. This article breaks down three stocks from our Dividend Powerhouses screener that combine 5%+ yields with covered, growing payouts, helping you aim for steadier income from strong businesses.\nThe three dividend powerhouses...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-dividend-powerhouses-for-more-reliable-income-in-volatile","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-dividend-powerhouses-for-more-reliable-income-in-volatile","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XME","QBE.AU","BK7501","BK7511","VIG","BK4588","BK7508","BK4585","BK4535","CSL.AU","BK7034","BK7104","BK7506","UYM","EVN.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657400336","title":"3 Australian Dividend Stocks Paying Over 5% That Income Investors May Want To Check","url":"https://stock-news.laohu8.com/highlight/detail?id=2657400336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657400336?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:32","pubTimestamp":1786105954,"startTime":"0","endTime":"0","summary":"With global central banks holding policy rates high as inflation pressures linger, cash in the bank can feel stuck while prices keep rising. Reliable dividends over 5% start to look more appealing when income is hard to grow through interest alone. This article walks through three dividend powerhouses from the 3%+ Yield screener that combine higher yields with coverage and stability to help anchor a long term portfolio.\nThe three stocks in this article are just a starting sample, and the full...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-paying-over-5-that-income-inves","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-paying-over-5-that-income-inves","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RING","DUST","PHYS","BAR","CSL.AU","PPI","AAAU","XME","IAUM","CEF","DGP","DZZ","GDXY","USG","GDX","JDST","SGDM","VOTE","ISBC","IAU","UGL","GLL","UYM","XJO.AU","SGOL","SHNY","GDXJ","BEGS","DECU","OUNZ","XAO.AU","FGDL","DBC","DULL","IAUI","GOLY","GOAU","SPHQ","GLDM","BTGD","GLTR","PICK","GDXU","XKO.AU","EVN.AU","GBUG","JNUG","QBE.AU","VIG","GDXD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615916","title":"Pediatric ANDEMBRY Phase 3b Success Might Change The Case For Investing In CSL (ASX:CSL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615916","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657615916?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:40","pubTimestamp":1786084840,"startTime":"0","endTime":"0","summary":"CSL has reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema, showing a safety profile consistent with earlier studies and treatment responses that kept most participants attack-free over 12 months.\nThis progress in extending ANDEMBRY’s use to younger pediatric patients highlights CSL’s push to deepen its presence in rare disease prophylaxis through factor XIIa inhibition.\nWe’ll now examine how the positive...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/pediatric-andembry-phase-3b-success-might-change-the-case-fo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/pediatric-andembry-phase-3b-success-might-change-the-case-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0728928796.USD","BK7508","LU1169590202.USD","BK7067","CSL.AU","BK7511","BK7501","SGXZ23171101.USD","BK4086","CSL","SG9999004303.SGD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657662564","title":"CSL Says European Commission Revokes Marketing Authorization for Tavneos","url":"https://stock-news.laohu8.com/highlight/detail?id=2657662564","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657662564?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:24","pubTimestamp":1786062287,"startTime":"0","endTime":"0","summary":"CSL  and Vifor Fresenius Medical Care Renal Pharma said the European Commission revoked the marketing authorization for the Tavneos drug following a recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use , according to a Thursday statement.Tavneos was developed as a treatment for adults with the main forms of ANCA-associated vasculitis, a potentially life-threatening disease where the immune system mistakenly attacks the body's own blood vessels.The marketing authorization was revoked due to concerns related to data handling in a phase 3 trial before approval was granted, with the CHMP concluding that a positive benefit-risk balance for the drug could no longer be established.\"While we are disappointed by the decision, we respect the outcome of the regulatory process and are committed to implementing it in full,\" CSL and Vifor Fresenius said.Tavneos will no longer be available for prescribing in the European Union and European Economic Area co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","SGXZ23171101.USD","BK4087","CSL","BK7067","SG9999004303.SGD","BK4086","CSL.AU","BK7511","LU0728928796.USD","LU1169590202.USD","CHMP","BK7508","BK7501","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657060","title":"Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657060?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:12","pubTimestamp":1786047154,"startTime":"0","endTime":"0","summary":"Arcturus Q2 revenue falls sharply on CSL Seqirus deal endOverviewMessenger RNA medicines company's Q2 revenue fell sharply yr/yr due to CSL Seqirus collaboration terminationQ2 net loss widened yr/yr, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","BK4533","BK4139","BK4585","WDNA","BK4548","GNOM","CSL.AU","BK4501","BK4551","BK4534","BK4568","MRNA","IDNA","BK7511","BK4588","ARCT","BK7501","BK4532","BK7508","MRNY","LGHT","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657550279","title":"EU Revokes Marketing Authorisation for CSL-Partnered Tavneos in EU, EEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657550279","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657550279?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:20","pubTimestamp":1785997251,"startTime":"0","endTime":"0","summary":"EU revokes marketing authorisation for CSL-partnered TAVNEOS in EU, EEAEU regulators revoked the marketing authorization for TAVNEOS (avacopan), removing it from prescribing across the EU and EEA.The ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL2Gc2r7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7508","BK7501","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502897","title":"CSL Ltd - European Commission Adopts Decision to Revoke Marketing Authorisation for Tavneos in the European Union and European Economic Area Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502897?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996070,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44225J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7511","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502392","title":"CSL Ltd - Tavneos Will no Longer be Available for Prescribing in the EU and Eea","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502392?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996070,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44225J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502318","title":"CSL Ltd - Committed to Implementing Decision in Full","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502318?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44225J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657503965","title":"US FDA Approves First mRNA Flu Shot from Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503965","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657503965?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:17","pubTimestamp":1785982652,"startTime":"0","endTime":"0","summary":"US FDA approves first mRNA flu shot from ModernaAug 5 (Reuters)-The U.S. Food and Drug Administration has approved Moderna'sMRNA.Oflu vaccine for people aged 50 and older, the company said on Wednesda","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4N43Q1QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU1989771016.USD","IE0034235188.USD","LU0553294199.USD","LU0823416689.USD","LU0964806797.USD","LU1267930813.SGD","MRNX","LGHT","LU0047473722.EUR","LU0738911758.USD","LU0949170772.SGD","WDNA","LU1923622614.USD","LU0171276677.USD","BK7508","LU1084165304.USD","LU2355687059.USD","LU0158827948.USD","LU0757432116.USD","LU0784385170.HKD","MRNA","BK7067","LU0496365809.HKD","LU0128525929.USD","LU1989772840.SGD","LU0122379950.USD","LU2539964713.USD","LU0545039389.USD","LU1119994496.HKD","03165","BK4588","CSL.AU","LU1015430645.USD","LU1153584641.USD","MRNY","IE00BFTCPJ56.SGD","LU0310799852.SGD","GNOM","AZN.UK","LU2112291526.USD","LU1863844665.USD","LU1057294990.SGD","LU0784383803.USD","BK7511","LU0128525689.USD","LU2091194634.USD","IDNA","LU0289739699.SGD","LU1487256676.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639527","title":"QBE Stock Leads 3 Australian Dividend Shares Offering Income and Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639527","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639527?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:28","pubTimestamp":1785958120,"startTime":"0","endTime":"0","summary":"Dividend Powerhouses can appeal to investors who want current income backed by companies that keep paying, rather than just hoping for price swings. With global growth mixed, inflation signals uneven and central banks watching energy prices and wage trends, a focus on well covered, stable and growing dividends can help bring some structure to a portfolio. This Dividend Powerhouses screener looks for yields above 5% that are supported by the underlying business. In the sections that follow,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/qbe-stock-leads-3-australian-dividend-shares-offering-income","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/qbe-stock-leads-3-australian-dividend-shares-offering-income","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PPI","DUST","AAAU","GOAU","GDXD","JDST","JNUG","RING","USG","GLL","BAR","GDXU","GDXY","PICK","PMDE","GXDW","BTGD","IAUM","CEF","DECU","GDX","DZZ","DULL","UGL","XKO.AU","FEBU","SHNY","XME","OUNZ","PHYS","XJO.AU","VOTE","SGOL","SGDM","IAU","XAO.AU","CSL.AU","GBUG","GOLY","DGP","FGDL","IAUI","GLDM","GLTR","EVN.AU","UYM","DBC","BEGS","GDXJ","QBE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657598900","title":"CSL Sets Investor Briefing for Full-Year Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657598900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657598900?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:43","pubTimestamp":1785883409,"startTime":"0","endTime":"0","summary":"CSL sets investor briefing for full-year resultsCSL will release its 2026 full-year financial result on Aug. 18, 2026.Investor and analyst briefing set for 10:00 a.m. AEDT on Aug. 18, 2026; webcast at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL7sQz4c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7511","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530463","title":"iBio Names Endocrinologist Molly Carr as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530463","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530463?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:06","pubTimestamp":1785841618,"startTime":"0","endTime":"0","summary":"iBio names endocrinologist Molly Carr as chief medical officeriBio named endocrinologist Molly Carr as chief medical officer to lead global clinical strategy, medical affairs, regulatory work for its ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLbLNm32:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1487256676.USD","BK4112","LU1309081286.SGD","LU1202635105.USD","IBIO","SG9999014013.SGD","LU1983299246.USD","LU0306806265.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","LU1481599808.USD","GSK.UK","LU1670756490.USD","LU0306807586.USD","LU1015430645.USD","LU0225284248.USD","LU1645745479.HKD","LU0161305163.EUR","LU0987226296.USD","BCDF","BK7501","LU0545562505.USD","NDAQ","LU0971552830.HKD","LU1228905037.USD","IE00B64PRP62.GBP","LU1228905540.USD","BK4568","LU0225771236.USD","LU2089984988.USD","LU0203347892.USD","IE00BKPKM429.USD","LU0225283273.USD","IE00BGHQF748.EUR","CSL.AU","LU0321505439.SGD","BK4585","LU0203345920.USD","LU1302929846.USD","LU1400636491.USD","LU2468319806.SGD","LU0109981661.USD","LU0575583348.USD","IE00B3T34201.USD","LU1098665638.USD","IE00BWDBJ516.SGD","LU0557290698.USD","LU1035777561.USD","LU1046248800.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656772588","title":"Australian Dividend Stocks Worth A Closer Look For Long Term Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2656772588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656772588?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:27","pubTimestamp":1785796057,"startTime":"0","endTime":"0","summary":"Dividend income has fresh appeal right now, with inflation readings easing in several regions and government bond yields swinging around as central banks weigh their next steps. For investors who want income that does not rely only on bond markets, the Dividend Powerhouses screener focuses on companies with a 5%+ yield that is well covered, growing and stable. That combination can help you target cash flow while keeping an eye on sustainability. In this article you will see three of the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/australian-dividend-stocks-worth-a-closer-look-for-long-term","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/australian-dividend-stocks-worth-a-closer-look-for-long-term","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EVN.AU","GLTR","USG","FGDL","CSL.AU","DGP","DUST","GLDM","XAO.AU","XJO.AU","DULL","VIG","XKO.AU","DECU","GBUG","DZZ","GOLY","GLL","SGOL","GDXD","IAUI","VOTE","JDST","XME","PICK","SPHQ","CEF","OUNZ","PHYS","GDXJ","IAUM","JNUG","GDX","GDXU","DBC","PPI","GDXY","AAAU","SHNY","BTGD","RING","SGDM","NST.AU","BEGS","GOAU","IAU","PMDE","BAR","UYM","UGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656345864","title":"CSL Stock And Australian Gold Miners Offering Dividend Yield Above 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656345864","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656345864?lang=en_us&edition=fundamental","pubTime":"2026-08-03 02:13","pubTimestamp":1785694430,"startTime":"0","endTime":"0","summary":"Global inflation, interest rate uncertainty and uneven growth across regions have pushed many investors to pay closer attention to steady income rather than chasing fast-moving stories. That is where Dividend Powerhouses 3%+ Yield stocks can help. The screener focuses on companies with dividend yields above 5% that appear well covered, growing and relatively stable, which can be appealing when bond markets and energy prices are pulling sentiment in different directions. In this article, you...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-australian-gold-miners-offering-dividend-yield","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-australian-gold-miners-offering-dividend-yield","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GLDM","DUST","PHYS","BAR","CEF","IGLD","XJO.AU","GDX","JNUG","GBUG","OUNZ","XAO.AU","GDXJ","GOLY","SGDM","IAU","XME","SHNY","NST.AU","USG","GLL","XKO.AU","DZZ","VIG","GOAU","PPI","STW.AU","GDXY","IAUM","RING","BBOZ.AU","PICK","UGL","JDST","CSL","UYM","EVN.AU","AAAU","IAUI","CSL.AU","DGP","GDXU","GLTR","SGOL","BTGD","DULL","BEGS","GDXD","FGDL","DBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656194823","title":"CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2656194823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656194823?lang=en_us&edition=fundamental","pubTime":"2026-08-02 01:23","pubTimestamp":1785604990,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has drawn fresh attention after reporting positive top-line Phase 3b results for its hereditary angioedema therapy ANDEMBRY in children aged 2 to 11 years, supporting potential expanded pediatric use.\nSee our latest analysis for CSL.\nThe ANDEMBRY update comes as CSL trades at A$123.06, with a 7 day share price return of 7.74% and a year to date share price decline of 28.44%. The 1 year total shareholder return is down 52.25%, pointing to weak long term momentum despite a recent...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-following-andembry-trial-results-still-looks-chea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-following-andembry-trial-results-still-looks-chea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169590202.USD","SGXZ23171101.USD","CSL.AU","BK7511","BK7067","BK4086","BK7501","LU0728928796.USD","LU1169589451.USD","CSL","SG9999004303.SGD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396122","title":"CSL Stock And 2 Australian Dividend Shares Backed By Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396122","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656396122?lang=en_us&edition=fundamental","pubTime":"2026-08-01 00:16","pubTimestamp":1785514612,"startTime":"0","endTime":"0","summary":"With inflation, interest rate questions and energy prices all pulling markets in different directions, many investors are looking for income that feels steadier than short term sentiment. Dividend Powerhouses, sometimes called Dividend Aristocrats, focus on companies with yields above 5% that are covered by earnings, growing and relatively stable. That combination can appeal if you want your portfolio to be paid while you wait for clearer signals from central banks and growth data. This...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-backed-by-earning","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-backed-by-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL","CSL.AU","XJO.AU","XKO.AU","XAO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655435336","title":"Australian Shares Log Best Month Since February as Rate-hike Worries Ease","url":"https://stock-news.laohu8.com/highlight/detail?id=2655435336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655435336?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:25","pubTimestamp":1785482759,"startTime":"0","endTime":"0","summary":"REFILE-Australian shares log best month since February as rate-hike worries easeRemoves extraneous word from fourth bulletS&P/ASX 200 edges up 0.1% on FridayBenchmark logs best month since FebruaryASX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","FMG.AU","BK7511","BK7129","LU0171293334.USD","LU0654597011.USD","LU0612318971.USD","LU1078025761.USD","LU1046248800.SGD","LU0345780950.USD","LU0831103253.SGD","BK4585","LU0345777147.USD","LU0511384066.AUD","IE00BQJZX424.USD","LU0708995401.HKD","LU0320765059.SGD","MSCI","LU0456854461.SGD","FDIQ","LU0971552830.HKD","LU1309081286.SGD","LU0109391861.USD","LU0630314457.HKD","LU0971552673.USD","LU0266512127.USD","LU0672654240.SGD","WOW.AU","SG9999002521.SGD","SG9999001143.SGD","RIO.UK","LU0264606111.USD","LU0572939691.SGD","LU2265009873.SGD","LU0289960550.SGD","CSL.AU","LU0175139822.USD","LU0330918003.SGD","LU0955669360.SGD","LU1302929846.USD","BHP.AU","LU0612318385.USD","IE0034235071.USD","IE00B3M56506.USD","BK7507","LU0572940350.SGD","BK4112","LU1023059493.AUD","BK7040","RIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655809269","title":"CSL Stock And QBE Shares For Dividend Income Above 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655809269","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655809269?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:14","pubTimestamp":1785420860,"startTime":"0","endTime":"0","summary":"Dividend Powerhouses with 5%+ yields and solid coverage can be especially appealing when global growth looks mixed, inflation stays uneven, and central banks keep investors guessing on rates. Reliable income from well covered and stable dividends can help smooth out some of that noise and give you a clearer sense of what you are getting paid to wait. This article focuses on three stocks from the Dividend Powerhouses screener that combine higher yields with a history of maintaining and growing...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-qbe-shares-for-dividend-income-above-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-qbe-shares-for-dividend-income-above-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IAUM","GBUG","UYM","BTGD","PPI","BEGS","KGLD","QBE.AU","BAR","XME","GOAU","EVN.AU","YGLD","CSL.AU","IAU","GDXD","GDXY","AAAU","PICK","RING","CEF","JNUG","FGDL","OUNZ","SGDM","GDXU","GLL","SHNY","DUST","JDST","IGLD","SGOL","VIG","DBC","PHYS","DGP","GOLY","GLTR","GLDM","DULL","IAUI","CSL","BGLD","DZZ","DGZ","GDX","UGL","GLDY","GDXJ","USG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655296468","title":"Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2655296468","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655296468?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:27","pubTimestamp":1785382062,"startTime":"0","endTime":"0","summary":"CSL recently reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 with hereditary angioedema, showing a safety profile in line with earlier studies and that most participants remained attack-free over 12 months.\nThe company now plans regulatory filings to extend ANDEMBRY’s indication to younger children, potentially widening treatment options in a part of the HAE population where approved long-term prophylactic choices remain limited.\nWe’ll now...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","SG9999004303.SGD","BK4086","BK7067","LU0728928796.USD","LU1169589451.USD","CSL","BK7501","BK7511","BK7508","SGXZ23171101.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}